8-K/A: INVO Bioscience Secures $850,000 in Funding Through Share Purchase Agreement with Triton Funds LP

INVO Bioscience has entered into an agreement with Triton Funds LP to sell up to 1,000,000 shares of common stock for gross proceeds of up to $850,000.

Summary

• INVO Bioscience has entered into a purchase agreement with Triton Funds LP to sell up to 1,000,000 shares of its common stock.
• The agreement could provide the company with gross proceeds of up to $850,000.
• Triton will purchase the shares at a price of $0.85 per share.
• The purchase agreement expires on the earlier of the sale of all shares or December 31, 2024.
• Individual sales of shares are limited to ensure Triton's beneficial ownership does not exceed 9.99% of outstanding shares.
• The total number of shares issued to Triton may not exceed Nasdaq Listing Rule 5635(d) requirements, unless shareholder approval is obtained.
• INVO Bioscience will file a prospectus supplement to its existing registration statement to cover the offering.
• Triton's obligation to purchase shares is conditional on the filing of the prospectus supplement and the registration statement remaining effective.
• Triton is obligated to purchase shares from time to time as directed by INVO Bioscience.
• Triton has agreed not to engage in short selling of INVO Bioscience shares during the term of the agreement.
• INVO Bioscience also sold private placement warrants to Triton to purchase up to 1,000,000 shares at an exercise price of $2.00 per share.
• The warrants are immediately exercisable and expire five years from the issuance date.
• The warrants can be exercised through a cashless exercise if a registration statement is not effective.
• The exercise of warrants is limited to ensure Triton's ownership does not exceed 9.99% of outstanding shares.
• The company may not issue shares upon exercise of the warrants if it would exceed 19.9% of the company's outstanding common stock without shareholder approval.

Sentiment

Score: 6

Explanation: The document indicates a necessary capital raise for the company, which is a positive for funding operations but also dilutes existing shareholders. The terms are fairly standard, so the sentiment is neutral to slightly positive.

Positives

• The agreement provides INVO Bioscience with a potential influx of up to $850,000 in gross proceeds.
• The purchase agreement provides a flexible funding mechanism, allowing INVO Bioscience to draw down capital as needed.
• Triton is obligated to purchase shares as directed by INVO Bioscience, providing a reliable source of funding.
• The agreement includes a restriction on short selling by Triton, which may help stabilize the company's stock price.
• The warrants provide a potential future source of capital if exercised.

Negatives

• The sale of shares will dilute existing shareholders' ownership.
• The exercise of warrants could further dilute existing shareholders' ownership.
• The company is reliant on Triton's willingness to purchase shares as directed.
• The company may need to seek shareholder approval to issue more shares if the 19.9% limit is reached.
• There is no established trading market for the private placement warrants.

Risks

• The actual amount of capital raised may be less than $850,000 depending on market conditions and the company's needs.
• The company's stock price could be negatively impacted by the issuance of new shares.
• The company is subject to Nasdaq listing rules regarding the issuance of shares.
• The company is reliant on the effectiveness of its registration statement and prospectus supplement.
• The warrants may not be exercised if the share price does not reach the exercise price of $2.00.

Future Outlook

The company intends to utilize the funds raised for general corporate purposes and operations. The actual amount of capital raised will depend on market conditions and the company's needs. The company may need to seek shareholder approval to issue more shares if the 19.9% limit is reached.

Industry Context

This type of financing is common for small-cap companies seeking to raise capital. The use of a purchase agreement with a fund like Triton allows for flexible access to capital as needed. The inclusion of warrants is also a common practice to incentivize investors.

Comparison to Industry Standards

• Similar small-cap biotech companies often use private placements and warrant offerings to raise capital.
• The terms of the agreement, such as the share price and warrant exercise price, are within the typical range for such transactions.
• The 9.99% ownership limitation is a common clause to avoid triggering certain regulatory requirements.
• The use of a shelf registration statement and prospectus supplement is a standard procedure for public companies.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company's employees may benefit from the increased financial stability.
• The company's creditors may view the capital raise positively.
• The company's customers and suppliers may not be directly impacted by this transaction.

Next Steps

• INVO Bioscience will file a prospectus supplement to its existing registration statement.
• The company will determine the timing and amount of share sales to Triton based on market conditions and funding needs.
• The company may seek shareholder approval to issue more shares if necessary.
• Triton will purchase shares as directed by INVO Bioscience.

Key Dates

Keywords

share purchase agreement, private placement warrants, capital raise, equity financing, common stock, Triton Funds LP, dilution, Nasdaq listing rules, prospectus supplement, registration statement